Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.58 |
| ▸ | CA9 | Q16790 | 3/20 | 0.58 |
| ▸ | CA12 | O43570 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | MMP2 | P08253 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.46 |
| ▸ | GHSR | Q92847 | 8/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | SCD | O00767 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4802253 | 0.83 | CA12 (0.58) | CA2CA9CA12CA1MMP2 | |
| SCHEMBL4804011 | 0.79 | CA12 (0.55) | CA2CA9CA12CA1MMP2 | |
| SCHEMBL7058218 | 0.77 | CA2 (0.51) | CA2CA9CA12CA1MMP2 | |
| SCHEMBL13742923 | 0.77 | CA2 (0.61) | CA2CA9CA12CA1MMP2 | |
| SCHEMBL4201541 | 0.77 | SCD (0.58) | CA2CA9CA12CA1MMP2 | |
| SCHEMBL4804285 | 0.77 | CA2 (0.55) | CA2CA9CA12CA1MMP2 | |
| SCHEMBL4796613 | 0.77 | CA2 (0.51) | CA2CA9CA12CA1MMP2 | |
| SCHEMBL7058217 | 0.75 | CA2 (0.54) | CA2CA9CA12CA1MMP2 | |
| SCHEMBL338810 | 0.74 | LTA4H (0.70) | CA2CA9CA12CA1MMP2 | |
| SCHEMBL5052625 | 0.74 | LTA4H (0.50) | CA2CA9CA12CA1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381728-B2 | Piperazine derivatives useful for the treatment of gastrointestinal disorders | GLAXO GROUP LIMITED (GB) | 2008-06-03 | — | — | US | disclosed |
| US-20070259877-A1 | Piperazine Derivatives Useful for the Treatment of Gastrointestinal Disorders | GLAXO GROUP LIMITED | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259877-A1 | Piperazine Derivatives Useful for the Treatment of Gastrointestinal Disorders | GHSR, GHRHR, GIPR | CA2 2384/4885CA9 3811/4885CA12 3520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.